Terapia S.A.

Cluj-Napoca 36 trials 2 recruiting

36 Registered trials

2 Currently recruiting

Organisation

Terapia S.A.

Location

Cluj-Napoca, Romania

Identifier

ORG-100000123

Address

Strada Fabricii Nr. 124, 400640, Romania

Departments

Clinical Pharmacology and Pharmacokinetics
CPP Department

Clinical trials at this site (36)

Search interface

A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Lisd… Pending

2024-517956-36-00 ADHD 2
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study c… Pending

2025-520618-76-00 ulcerative colitis 2
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence stud… Pending

2025-521598-16-00 ulcerative colitis 2
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence stud… Pending

2025-522106-20-00 ulcerative colitis 2
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover, bioavailability study comparing Bupropi… Pending

2025-523410-84-00 Seasonal affective disorder 2
An open label, balanced, randomized, three treatment, three period, three sequence, single dose, crossover study to assess the effect of foo… Pending

2025-523411-11-00 Seasonal affective disorder 3
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametin… Pending

2025-524267-20-00 Adjuvant treatment of BRAF V600E or V600K mutation-posi 2
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatini… Pending

2025-524935-38-00 Acute Lymphoblastic Leukemia (Ph+ ALL) 2
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatin… Recruiting

2025-524311-37-00 chronic myeloid leukemia 2 2026-05-19
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMA… Recruiting

2025-522097-36-00 alopecia areata 3 2025-11-19
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribav… Ended

2025-523487-21-00 cytomegalovirus (CMV) infection and/or disease that is 2 2026-05-05
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study c… Ended

2025-520617-31-00 ulcerative colitis 2 2025-09-12
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523838-13-00 plaque psoriasis 2 2026-03-24
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523839-18-00 plaque psoriasis 2 2026-03-24
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexa… Ended

2025-521224-29-00 ADHD (Attention Deficit Hyperactivity Disorder) 2 2026-02-20
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarith… Ended

2024-520153-21-00 Infectious diseases 2 2026-01-29
A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupr… Ended

2024-516035-27-00 major depressive illness 2 2026-01-09
A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupr… Ended

2024-516034-35-00 major depressive illness 2 2025-12-05
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulo… Ended

2024-517642-34-00 Benign prostatic hyperplasia (BPH) 2 2025-11-10
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulo… Ended

2024-517625-72-00 Benign prostatic hyperplasia (BPH) 2 2025-10-16
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexa… Ended

2024-513517-12-00 ADHD 2 2025-10-01
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolit… Ended

2024-519801-36-00 Myelofibrosis, polycythemia vera, acute and chronic gra 2 2025-07-14
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Naltrex… Ended

2024-519776-20-00 Alcohol dependence 2 2025-05-12
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Enzalutam… Ended

2024-518209-16-00 Prostate cancer 2 2025-04-14